The inherited platelet glycoprotein deficiencies, Glanzmann thrombasthenia (GT) and Bernard Soulier syndrome (BSS) are rare but important long-term bleeding disorders. Once diagnosed, affected patients should be referred to a specialist centre for bleeding disorders for general advice and ongoing management. Patients do not require prophylactic treatment and so the management of GT and BSS focuses around prophylactic treatment prior to high risk procedures and treatment in response to non-surgical bleeding events and, in women, the management of menorrhagia and pregnancy. There is no consistent approach to the treatment or prevention of bleeding complications. Management must be tailored for each individual and the approach may not be the same for different events, even for the same patient, depending on the type of accident or invasive procedure, the extent of bleeding and the presence or not of platelet refractoriness.
Background

Glanzmann thrombasthenia (GT)
In 1918 Eduard Glanzmann described a bleeding disorder "Hereditare Hamorrhagische Thrombasthenia" characterised not by a reduction in platelet numbers but by a functional disorder that Glanzmann diagnosed by finding a slow or absent clot retraction and a prolonged bleeding time (BT) (Stevens & Meyer, 2002) . Glanzmann thrombasthenia (GT) is inherited in a recessive manner with an incidence of 1 per million but this increases to 1 in 200 000 in areas of high consanguinity. The genetic defect occurs in ITGA2B (GTIIb) or ITGB3 (GTIIIa) genes on chromosome 17; details of the mutations can be found on the GT international database https://glanzmann.mcw.edu/ (Nurden & Pillois, 2017) . The mutations lead to a quantitative (type 1 and type 2) or qualitative (type 3) deficiency in platelet membrane glycoprotein (GP)IIb/IIIa resulting in impaired platelet aggregation and a prolonged BT and/or prolonged closure times on the platelet function analyser (PFA-100). The mutations produce platelets that, although normal in number and capable of migrating to the site of vascular injury, are unable to form platelet aggregates or an effective primary haemostatic plug.
Bernard Soulier syndrome (BSS)
Thirty years later, Bernard and Soulier (1948) described a bleeding disorder characterised by a prolonged bleeding time and the presence of a macro-thrombocytopenia. The male index case described by Bernard and Soulier suffered repeated bleeds throughout his life and died when aged 28 years of a brain haemorrhage following a fight in a bar (Lopez et al, 1998; Stevens & Meyer, 2002) . BSS is a rare disorder usually with an autosomal recessive inheritance and an incidence of about 1 per million though it is more common in families with parental consanguinity (Macheta et al, 1997) . BSS caused by inheritance of two mutations is often referred to as bi-allelic or bBSS. In a small number of patients BSS is autosomal dominant (Lopez et al, 1998; Vettore et al, 2008) . In these cases, BSS is caused by a single mutation in the Gp1b-IX-V platelet membrane GP complex so is mono-allelic and referred to as mBSS. mBSS almost always has a less severe clinical course than bBSS.
Mutations of the Gp1b-IX-V gene complex (comprising GP1BA, GP1BB, GP9 and GP5) affect the binding of the platelets' surface membrane to von Willebrand factor (VWF), which is in turn, bound to the sub-endothelium at the site of vessel damage and thus interferes with primary haemostatic plug formation (Alamelu & Liesner, 2010) . Gp1b-IX-V mutations also interfere with normal clot formation by reducing the ability of thrombin at low concentrations to activate platelets (Peitsidis et al, 2010) . The same complex may also have an important role in normal platelet synthesis in the marrow, accounting for the thrombocytopenia and large platelets that characterise the syndrome (Lopez et al, 1998; Mhawech & Saleem, 2000) . Lanza (2006) described 47 different mutations in three of the four genes involved; 20 mutations in GP1BA, 16 mutations in GP1BB and 11 mutations in GP9. Lanza (2006) found no mutations in GP5 and this was still the case in 2015 (https://rarediseases.org/rarediseases/bernard-soulier-syndrome/).
Clinical presentation
GT in childhood George et al (1990) reviewed the data from 177 patients. Most patients were described prior to 5 years of age and 16 patients presented with neonatal petechiae. Epistaxis was the most common cause of severe bleeding and, in most females, menorrhagia was severe during the initial menses following menarche. Three intracranial haemorrhages are described; two after head trauma and the details of the third were unavailable. In total, 84% of patients required red cell transfusion; however, some patients never experienced severe bleeding. Although GT frequently presents during the neonatal period with petechiae and purpura, major bleeding, including intracerebral haemorrhage, is rare in the first 4 weeks of life (Awidi, 1984; George et al, 1990) .
In a study of 796 GT patients from Lahore (Iqbal et al, 2016) , the majority of patients developed bleeding symptoms during the first year of life although the mean age at diagnosis was 7 years. The commonest clinical presentations were easy bruising (76Á7%), epistaxis (62Á5%) and increased bleeding after minor trauma (47Á2%). Two of the 796 patients developed intracranial bleeding following falls. In general, patients diagnosed under 5 years of age were more likely to have severe bleeding.
BSS in childhood
bBSS also most often presents in infancy or early childhood usually as unexplained purpura or bruising, gingival bleeding or excess haemorrhage following surgical procedures or invasive dentistry; affected females often have moderate to severe menorrhagia (Lopez et al, 1998; Bolton-Maggs et al, 2006; Lanza, 2006; Alamelu & Liesner, 2010) . Some patients experience gastrointestinal haemorrhage and haematuria. Bleeding into joints and spontaneous intracerebral haemorrhage are uncommon (Alamelu & Liesner, 2010) and fatalities from bleeding are rare (Nurden, 2005) . However, BSS has a diverse clinical presentation with both variable severity of bleeding and age of onset. A minority of cases have a delayed presentation in adult life, many of which are in fact cases of mBSS (see below).
We recommend that GT and BSS should be included as part of the differential diagnosis in any child who presents with muco-cutaneous or severe bleeding; especially when there is a family history of bleeding and the initial coagulation screen is normal. Both conditions should also be considered in the investigation of non-accidental injury (NAI). Most of the cases of NAI in childhood occur in infants for whom investigation using platelet aggregation methods may be complicated by the relatively large volume of blood required and the lack of accepted normal ranges in children under 12 months of age (Harrison et al, 2011) . We recommend that the second line investigation of purpura or bruising suspected as being NAI includes either platelet function analysis using the platelet function analyser (PFA) or direct Platelet GP analysis (Ward et al, 2013) .
Glanzmann thrombasthenia in adults
Although patients with severe forms of GT generally present early in life, in some cases, the haemorrhagic symptoms may only become obvious in adolescence or adulthood (George et al, 1990) . In GT, the incidence of severe bleeding in general decreases with age. It is also useful to remember that there is no correlation between the levels of GPIIb/IIIa and severity of bleeding in GT (George et al, 1990; Poon et al, 2016) . This is possibly because the bleeding phenotype in GT is multifactorial and this may explain the variability in bleeding symptoms sometimes seen sin different members of the same family affected by the same mutation (Poon et al, 2016) . The exception to this is the stable, milder bleeding phenotype seen in association with the ITGA2 (platelet a2) C807T polymorphism (D'Andrea & Margaglione, 2003) . Chromosomal rearrangements that can be associated with the later development of leukaemia should be excluded in patients diagnosed with GT, who do not have a family history (Harrison et al, 2011) .
Bernard Soulier syndrome in adults BSS is usually described as an autosomal recessive macrothrombocytopenia with giant platelets (bBSS). Most cases of BSS are diagnosed in childhood but some patients who may have milder, autosomal dominant form of BSS may present later in life (Alamelu & Liesner, 2010) .
The milder forms of BSS, where only one BSS allele is mutated (mBSS), may be easily missed (Noris et al, 2012; Balduini et al, 2013) . Bleeding symptoms are reduced in many of the affected individuals because the total circulating platelet mass is largely conserved in patients with macrothrombocytes but with only a mild to moderate thrombocytopenia (Bessman et al, 1981) .
One of the important mono-allelic mutations is the 515C>T mutation of GP1BA, the Bolzano mutation (Ware et al, 1993; Margaglione et al, 1999; Nurden, 2005 and Andrews & Berndt, 2015) . In these patients, platelet size is increased but the thrombocytopenia is usually mild (average platelet count of 81 9 10 9 /l), and bleeding is minimal (Noris et al, 2012) . A few individuals have been described where the platelet counts have been lower, and patients suffered more severe haemorrhagic episodes (Noris et al, 2012) . In these patients, platelet aggregation in response to ristocetin will be normal or only marginally reduced and flow cytometry shows only a mild reduction of the GPIb-IX-V receptor.
Other mutations similar to the Bolzano mutation have been described which can give rise to the same clinical and laboratory findings. These mBSS mutations should be considered in patients with milder bleeding symptoms and only mild macrothrombocytopenia (Balduini et al, 2013) .
Laboratory diagnosis
GT
The International Society on Thrombosis and Haemostasis (ISTH) first line investigations for patients with platelet disorders include full blood count (FBC), blood film, light transmission aggregometry (LTA), platelet granule release and flow cytometry for platelet GPs. The use of the PFA-100 and/or skin bleeding time are not recommended due to poor sensitivity, specificity and low reproducibility (Gresele, 2014) , though many patients will have undergone these tests prior to the diagnosis being suspected, particularly where there was no definite family history. The FBC and blood film are usually normal in GT, with a platelet count at the lower end of the normal range. Occasional families have been described with moderate thrombocytopenia (platelet 50-100 9 10 9 /l) or with macro-thrombocytopenia (Nurden et al, 2012a) . The LTA for GT is characteristically absent to all agonists other than to ristocetin [adenosine diphosphate (ADP), collagen, thrombin and arachidonic acid]. The LTA in response to ristocetin is usually maintained but may be reversible or cyclic. Flow cytometry confirms the absence (type 1) or reduction (type 2) in the platelet membrane GPIIb/IIIa. In variant (type 3) GPIIb/IIIa may be expressed but is not functional. In variant forms diagnosis can be made on flow cytometry with PAC-1 to demonstrate the inability of platelet binding to activated GP IIa/IIIa (Bolton-Maggs et al, 2006) . The platelet physiology subcommittee of ISTH also encourages the use of a bleeding assessment tool (BAT). Reports of use of the ISTH-BAT in patients with GT have found this to be predictive for the platelet defects in patients of different ages. (Rashid et al, 2016) .
BSS
In most cases, the discovery of a moderate to mild thrombocytopenia on the FBC and the finding of a macro-thrombocytopenia on blood film examination in a child with abnormal bruising or bleeding alerts the haematologist to the possibility of the diagnosis of BSS. The platelet count is variable; varying from <10 9 10 9 / l to normal (De La Salle et al, 1995; Lopez et al, 1998) , Kunishima et al, 1997) . Most have platelet counts between 20 and 100 9 10 9 /l (Lanza, 2006) . Platelet counts in BSS can also fluctuate in the same individual with time (Lopez et al, 1998) . The automated platelet count often underestimates the actual number of platelets because many of the platelets present in affected individuals' blood sample are larger than the size cut off that differentiates platelets from red cells; more accurate counts may be obtained using optical (Platelet-optical, PLT-O) or manual counting methods (Alamelu & Liesner, 2010) . Sysmex have recently developed a new method of counting platelets that uses inbuilt fluorescent labelling and flow cytometry to more accurately count platelets (Platelet-fluorescence, PLT-F; Park et al, 2014) . A study of this method concluded that the increased accuracy was achieved by using reagents that stained for intra-platelet mitochondria and messenger ribonucleic acid (mRNA), neither of which are present in red blood cells (Wada et al, 2015) . Such innovations should make it possible to more accurately quantify platelets in macrothrombocytopenic disorders, such as BSS. The PFA closure times are markedly increased in both the ADP and Epinephrine cartridges and the bleeding time is significantly prolonged (Harrison et al, 2002; BoltonMaggs et al, 2006) . LTA testing demonstrates reduced response to ristocetin that is not corrected by the addition of normal plasma thus distinguishing BSS from von Willebrand disease (VWD). Responses to ADP, collagen and arachidonic acid are normal, but in some cases there is a reduction in platelet aggregation in response to thrombin. (Bolton-Maggs et al, 2006; Lanza, 2006; Alamelu & Liesner, 2010) . In a significant number of BSS patients, the platelet count is low enough to make LTA unreliable; in some subjects even at counts of <120 9 10 9 /l. The United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) 2006 guidelines suggested either adjusting the platelet count of the control sample to that of the patients or using washed platelets where the platelet counts of both patient and control can be matched (Bolton-Maggs et al, 2006) .
Flow cytometric analysis (FCA) of platelet GPs demonstrates a moderate to marked reduction in CD42a (GpIX) and CD42b (Gp1ba). Flow cytometry has several advantages over LTA. FCA is less prone to pre-analytical variables, can be performed at very low platelet counts and requires a smaller volume of sample, making it particularly appropriate for the investigation of neonates, infants and young children (Cohn et al, 1997) . Finally, it is possible to identify the genetic abnormality by molecular genetics in both BSS and GT, thus making antenatal diagnosis possible for many affected families. 
Differential diagnosis of BSS
Finding a macrothrombocytopenia on microscopic examination of the blood film is an important component in the diagnosis of BSS. However other conditions may have similar blood film appearances and need to be considered in the differential diagnosis:
1 Heterozygotes for BSS (mBSS) are generally asymptomatic with normal blood films (Lopez et al, 1998 ) though a minority of heterozygote carriers of BSS have mild to moderate abnormal bleeding (Bolton-Maggs et al, 2006) and may have a macrothrombocytopenia (Lanza, 2006) . 2 Some patients are mis-diagnosed as immune thrombocytopenia (ITP) (Lopez et al, 1998; Nurden, 2005; Lanza, 2006; Pham & Wang, 2007) . A reported positive family history of 'ITP', failure of response to first line therapy with either steroids or immunoglobulin or where the bleeding symptoms are out of proportion to the platelet count should lead to a consideration of BSS as a possible diagnosis prior to the use of splenectomy or third line drug therapies which may potentially have significant side effects. 3 The other inherited causes of macrothrombocytopenia need to be considered:
a The May-Hegglin abnormality and myosin heavy chain 9 (MHY9) disorders can be differentiated from BSS by the presence of Dohle-like bodies in neutrophil cytoplasm (Hsia & Xenocostas, 2012) . b Grey Platelet syndrome may be suspected by the lack of intra-platelet granules (Kahr & Dror, 2012) and confirmed by electron microscopy. c Paris Trousseau Platelet disorder (PTPD) associated with Jacobsen syndrome is most often detected in an already diagnosed child and can be confirmed by cytogenetics. PTPD is associated with a deletion of the terminal end of the long arm of chromosome 11 that includes band 11q24.1, 11q terminal deletion disorder. d DiGeorge syndrome (DGS) is one of a group of phenotypically similar disorders-including velocardiofacial syndrome (VCFS, or Shprintzen syndrome) and conotruncal anomaly face (CTAF) syndrome that share a microdeletion of chromosome 22q11.2, a region known as the DGS critical region. 90% of individuals with the 22q11.2 deletion syndrome (22q11DS) are heterozygotes for BSS because the deletion most often includes the GP1B locus. Although a moderate macrothrombocytopenia is common in 22q11DS, unlike in non-22q11DS heterozygotes for mBSS, the defect is only rarely associated with bleeding symptoms and abnormal ristocetin-induced platelet aggregation (Rosa et al, 2011) , though in one study 70% of the 22q11DS patients had abnormal PFA closure times (Liang et al, 2007) . In 22q11DS the situation is further complicated by the 200-fold increase in the occurrence of immune thrombocytopenia (ITP) in these patients related to their underlying immunodeficiency. The risk of ITP increases as T cell numbers reduce with age (Akar & Adekile, 2007) . Rarely, the 22q11DS deletion can occasionally be associated with a co-existing MHY9 disorder. The gene that encodes for the non-muscle MYH9 (MYH9) is also located on 22q11. Saito et al, 2004 described a 22q11DS patient with a macro-thrombocytopenia and leucocyte inclusion bodies. Finally, cases of BSS have occurred in 22q11DS where loss of 22q11 on the affected allele has been associated with a microdeletion affecting the GP1BB gene on the 'unaffected' allele (Budarf et al, 1995) .
Treatment of GT and BSS
General principles
Because the patients do not require routine prophylaxis, the management of GT and BSS focuses around prophylactic treatment prior to high risk procedures and treatment in response to non-surgical bleeding events. However, routine follow-up and patient education are essential to ensure ongoing health and wellbeing. Patient education should focus on good dental hygiene, avoidance of high risk sports and the use of applied pressure for epistaxis. All cases should be registered with a specialist centre for bleeding disorders that can provide 24-h management facilities. Such patients should also be issued with an alert card which details the clinical condition and contact numbers for the specialist centre. It is imperative that in both severe and mild cases, the physician educates the patients and family of the risks associated with any situation where there is an increased likelihood of haemorrhage. Since nosebleeds and gum-bleeds are common bleeding problems in these patients, advice regarding practical measures, such as appropriate techniques to staunch blood loss, regular dental assessments and maintaining good oral hygiene, are important.
Patients need to be advised not to buy over the counter medications which may increase the risk of bleeding (BoltonMaggs et al, 2006) and that the patients inform any health care professionals who may prescribe them medications which interfere with platelet function; the list is not limited to non-steroidal anti-inflammatory drugs and aspirin, but several other drugs including antibiotics, antihistamines and psychoactive agents (George & Shattil, 1991) .
In all patients with confirmed BSS and GT, a family study should be initiated and counselling regarding the mode of inheritance is essential.
Supportive care should include iron replacement for anaemia secondary to menorrhagia or recurrent epistaxis. All patients should be vaccinated against hepatitis A and B. A dentist, nurse specialist and adolescent or general gynaecologist should all be involved in the patients' on-going care. As with any lifelong bleeding disorder, patients will transition from paediatric to adult service at an appropriate age and time for the patient.
Specific measures
Anti-fibrinolytic therapy
Anti-fibrinolytics, such as tranexamic acid, are the most widely used treatment for a patient with bleeding episodes. They are particularly useful for mucocutaneous bleeds, such as following dental procedures, epistaxis and menorrhagia. Used either alone or in combination therapy and, where appropriate, with other measures, such as nasal packing, compression sponges or hormonal treatment, they have been proven to be safe and effective.
Desmopressin (DDAVP)
Unlike the antifibrinolytics, DDAVP has little role to play in the platelet GP deficiencies. Theoretically the rise in acute reactants factor VIII and VWF along with increasing platelet adhesiveness might be advantageous (Lozano et al, 1999) . However, there is no evidence that DDAVP is at all effective in GT and there are only equivocal results in BSS (Nurden et al, 2012b) .
Platelet transfusions
Platelet transfusions are considered the first line treatment for patients undergoing major surgery or with severe bleeding or other bleeding episodes when anti-fibrinolytics and local measures have failed.
However, there are several issues with the use of platelets. There are the concerns that accompany the use of any blood product, including allergic reactions, volume overload, transfusion-related acute lung injury and the risk of transfusion-transmitted infections. Although rare, platelet transfusion is associated with the greatest risk of transfusion-transmitted bacterial infection (TTBI) This is because, unlike other blood components, platelets are stored at 20-24°C, which permits bacterial proliferation. The risk of TTBI is estimated to be approximately 1 in 12 000 for whole blood-derived platelet concentrates compared to 1 in 60 000 for apheresis platelets (Blajchman et al, 2005) though a more recent US study that tested units both at the time of collection and then again when the units were actually issued to patients, indicated that previous studies may well have under-estimated the risk of bacterial proliferation (Hong et al, 2016) .
The biggest concern in patients with BSS and GT with respect to platelet transfusions is the development of antibodies or platelet alloimmunisation. To minimise the risk of alloantibody formation against the missing platelet GPs, platelet transfusions should preferably be leucocyte-depleted and human leucocyte antigen (HLA)-matched. Whilst ideal, this may not be feasible in an unplanned event. Historical reviews have described antibody formation in up to 25-70% of patients (Santoro et al, 2010; Fiore et al, 2012) . Leucocyte depletion of blood products at the time of donation has reduced the rate of HLA antibody production but not eliminated the problem entirely. Since the United Kingdom (UK) implemented leucocyte-depletion of cellular blood components in 1999, the incidence of alloimmunisation has been significantly reduced but it may still be of the order of 10-25% (Williamson et al, 1994) .
Antibodies can also develop against the specific GPs that are deficient in GT and BSS (George et al, 1990) . In the international GT registry data, 65/218 (30%) of patients treated with different haemostatic agents developed platelet antibodies, of which 47 were against GPIIb/IIIa and 21 towards HLA. (Poon et al, 2016) . There is some evidence to show that GPIIb/IIIa antibodies are more likely to develop in patients with homozygous or compound heterozygous mutations totally lacking aIIbb3 than in others with some aIIbb3 expression; in one small study the risk was 80% of cases with no aIIbb3 expression versus 25% with less severe mutations (Fiore et al, 2012) . Thus, knowledge of the genetic mutation may be useful in GT patients given that platelet transfusions are best avoided in these patients to prevent the high risk of immunisation. Not as much is known about the risk of antibody formation in BSS but it is probably less frequent than in GT (Alamelu & Liesner, 2010) .
It is preferable to avoid platelet transfusions in women of reproductive age with GT because if they do develop antibodies to GPIb/IX or GPIIb/IIIa, these may transfer across the placenta during pregnancy and cause significant thrombocytopenia and bleeding in the fetus or the new-born infant (Siddiq et al, 2011) . In patients who have already developed antibodies and require platelet transfusions in severe bleeding situations, large doses of platelets should be administered along with recombinant human activated factor VII (rVIIa) (see below). Successful antibody removal using plasma exchange or immunoadsorption has been reported (Ito et al, 1991; Martin et al, 2002) .
At the time of diagnosis, all patients should be HLAtyped and have a baseline HLA antibody screen. In those patients who have already had platelet transfusions prior to the diagnosis being made, it is also important to look for platelet-specific antibodies. All patients who receive platelets should be tested for the presence of both HLA-and platelet GP-specific antibodies 2-3 months after the last transfusion. Platelet antibody detection should be undertaken prior to any surgical interventions or procedures where bleeding and, therefore, platelet transfusions may be anticipated and also at the time of booking in for antenatal care. It may be good practice to repeat this test routinely on an annual basis. For those who have developed antibodies, their patient alert card should clearly state this information.
Recombinant human activated factor VII
In 2004, rVIIa was approved for use in patients with GT for the treatment of bleeding episodes or prior to invasive procedures. The European Medicines Agency (EMA) approval is for GT patients who cannot be treated with a platelet transfusion either due to platelet antibodies or platelet refractory bleeding (http://www.ema.europa.eu/ema/index.jsp?curl=page s/medicines/human/medicines/000074/human_med_000936. jsp&mid=WC0b01ac058001d124). The recommended dose is 90 lg/kg administered 2-to 2Á5-hourly for at least three doses. Post-marketing pharmacovigilance on rVIIa was required by the EMA, leading to the international Glanzmann Thrombasthenia registry (https://glanzmann.mcw.edu/ ). The international GT registry collected data from 218 patients requiring 829 admissions for bleeding events between 2007 to 2011 (Di Minno et al, 2015) . 38% of bleeding episodes were managed with platelets and anti-fibrinolytics, 26% with anti-fibrinolytics alone, 13% with rVIIa and antifibrinolytics and 8% with rVIIa in combination with both platelets and anti-fibrinolytics. Treatment failures were rare and occurred in 2Á2% of bleeding events with no significant difference according to treatment regimen used. In the registry 38% of GT patients had a history of platelet antibodies or refractoriness to transfusions. The majority were treated with platelet transfusions (45%) compared to rVIIa (29%) or both (11%).
rVIIa is not licenced for use in BSS. However, rVIIa has been used successfully in patients with BSS (Almeida et al, 2003; Ozelo et al, 2005) and offers an alternative to platelets, particularly for procedures in BSS patients with platelet refractoriness.
The UKHCDO guideline for patients with platelet disorders including GT and BSS (Bolton-Maggs et al, 2006) and the British Society of Haematology (BSH) platelet transfusion guideline (Estcourt et al, 2016) both recommend the use of local measures and anti-fibrinolytics for less severe bleeding. rVIIa is preferred to platelet transfusions for non-life-threatening bleeding where the site of bleeding can be readily assessed. Unselected platelet transfusions should be used only in the setting of life threatening bleeding when a delay could be dangerous.
Different treatment regimens of rVIIa have been utilised but the greatest success in treating severe bleeds is with doses >80 lg/kg, at intervals of <2Á5 h for a minimum of three doses until bleeding stops. To reduce recurrence, one to three maintenance doses of rVIIa following initial treatment should be considered for severe bleeding. The use of continuous infusions of rVIIa does not appear to be effective in this setting (Poon, 2007) .
In the management of invasive procedures, the use of rVIIa is also often effective. Dental extractions are generally covered using one pre-operative dose at 90 lg/kg followed by two further doses at 2-hourly intervals and combined with anti-fibrinolytics. More invasive procedures are covered by at least 3 post-operative doses at 2-hourly intervals. In contrast to the treatment of severe bleeding (above), continuous infusions do appear to be as effective as bolus doses in preventing bleeding in the surgical setting. However, the total rVIIa usage was higher than with bolus treatment and thus cannot be routinely recommended, if only on cost grounds (Poon et al, 2004 (Poon et al, , 2015 Poon, 2007) .
The use of platelet transfusions is also effective in covering major procedures. The combination of rVIIa and platelet transfusions appears to be less successful than either platelets or rVIIa alone but this may well be due to the combination being used in higher risk procedures in higher risk patients (Poon et al, 2015) .
Stem cell transplantation
Allogeneic bone marrow transplantation is a curative option for GT and has been reported in one series of 19 patients with GT. The median age of transplant was 5 years (Ramzi et al, 2016) . Transplantation from a family-matched donor should be considered in patients with recurrent severe bleeding and platelet antibody development (McColl & Gibson, 1997; Bellucci et al, 2000) .
Fewer BSS patients have undergone stem cell transplantation (STC) but some have been successfully cured by transplantation (Locatelli et al, 2003; Rieger et al, 2006) . STC should also be considered in BSS patients with severe bleeding problems and/or platelet antibodies.
Gene therapy
Animal studies into the possibility of gene therapy for GT are already being carried out (Nurden, 2005) and BSS may also be a candidate disorder for gene therapy in the future.
Prevention of bleeding during surgical procedures
The Surgery In Platelet Disorders And Therapeutic Approach (SPATA) Study published its findings in 2017 (Orsini et al, 2017) . This is the largest study so far of the risk of surgery and peri-operative management regimens to try to minimise blood loss. In the SPATA study there were 829 surgical and dental procedures carried out on 423 patients. Of these, 182 invasive procedures were carried out on 89 patients with GT and 36 procedures in 17 patients with bi-allelic BSS. Full details of peri-operative management were not available for all subjects. However, the majority (n = 119) of the GT patients were administered platelets (n = 54) or antifibrinolytics (n = 30) or both (n = 35) with a significant minority having rVIIa alone (n = 24); only 6 GT patients had DDAVP given as monotherapy. In contrast, most of the BSS patients were managed with DDAVP as a single agent (n = 15) or in combination with antifibrinolytics (n = 23) with 18 subjects having platelets alone (n = 9) or antifibrinolytics alone (n = 9). No BSS patients in the study received rVIIa.
The overall risk of bleeding in the study across all the platelet disorders studies was 19Á7%, with the GT sub-group experiencing excess procedural bleeding in 29% and the BSS patients having the highest risk of all at 44%. A high World Health Organisation bleeding score of >2 or a high ISTH BAT score were associated with an increased risk of bleeding, as was a history of platelet refractoriness in the GT patients. 37Á5% of GT patients with platelet refractoriness had abnormal blood loss as opposed to 23Á3% who did not. From the data it was not possible to recommend any pre-operative regimen for GT and BSS patients. However, although only used in 32 procedures in GT patients, rVIIa alone appeared to be an effective even in severe cases when used as a single agent.
Issues specific to women with GT and BSS
Menorrhagia in BSS and GT
Heavy menstrual bleeding, as defined by bleeding lasting more than 7 days and/or a blood loss of more than 80 ml per menstrual cycle, is common in patients with BSS and GT and is sometimes the presenting symptom. It has been suggested that one in five women seeing a gynaecologist with menorrhagia may have an underlying inherited bleeding disorder although the exact prevalence of inherited platelet function disorders like BSS and GT in these cases is unknown (Kadir et al, 1998; Philipp et al, 2003; James et al, 2011) . In one study of 130 females with rare bleeding disorders over a period of 15 years, 44/50 beyond the age of menarche presented with menorrhagia (Vijapurkar et al, 2009) . 17 of these patients had GT and two were diagnosed as having BSS. The impact of menorrhagia on psychosocial well-being and quality of life can be considerable Karlsson et al, 2014) .
High dose DDAVP nasal spray is often useful in VWD patients with menorrhagia by increasing the VWF and factor VIII levels. High dose intranasal DDAVP has been assessed for the management menorrhagia in severe platelet disorders like BSS and GT but it was found to be ineffective (Alamelu & Liesner, 2010) .
Management of patients with BSS and GT with menorrhagia needs to be individualised and will require consultation with a gynaecologist in severe cases, i.e., refractory to standard treatments. The initial therapy of menorrhagia is with anti-fibrinolytics, such as tranexamic acid, given at weightappropriate doses and for the duration of the period. If the antifibrinolytic effect is inadequate, then treatment with hormone supplementation with either progesterone alone or progesterone with oestrogen may be contemplated if pregnancy is not considered (Bolton-Maggs et al, 2006) . High dose progesterone (e.g.; norethisterone 5-10 mg every 6-8 h) may be required in some patients at least for the initial part of the menstrual cycle. The dose can be decreased based on the absence of continued symptoms although withdrawal bleeding should be expected on stopping (Alamelu & Liesner, 2010) . Maintenance treatment can then be commenced with combined oral contraceptive pills, which may be desirable in some patients (George et al, 1990) . Markovitch et al (1998) has suggested high-dose conjugated oestrogens administered intravenously for 1-2 days for acute bleeding, although this is not common practice. Progestin-secreting intrauterine devices are increasingly being used to control menorrhagia in patients with bleeding disorders. The Mirena coil, (Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ, USA) containing levonorgestrel, is an intrauterine device used to reduce the severity of menstrual bleeding and improve quality of life in patients with menorrhagia and patients with inherited bleeding disorders (Kingman et al, 2004) . Insertion of such intrauterine devices may require specific haemostatic support (as in the case of minor surgeries, discussed later), because it is associated with an increased bleeding risk. Cultural or religious objections concerning the use of hormonal therapy, which is often the mainstay of management of menorrhagia, may create barriers to effective treatment.
Some patients still have troublesome menorrhagia despite the above measures and must be considered for surgical interventions such as uterine artery embolization, endometrial ablation and hysterectomy. Surgery is usually reserved for patients who have completed their family although may be required in rare cases with refractory or life-threatening bleeding.
Management of pregnancy in GT
In a publication of a single case series, a total of 26 pregnancies were described from three centres (Siddiq et al, 2011) . Ten babies (38%) were delivered by vaginal route and 13 (50%) by caesarean section and three pregnancies ended in spontaneous miscarriage. Postpartum haemorrhage was reported in 6/26 (23%) of pregnancies. The paper also reviewed 31 case reports describing 40 pregnancies in GT, which resulted in 38 live births. In half of the pregnancies, the mothers had experienced bleeding episodes during the antenatal period, predominantly epistaxis. Sixteen out of 22 (73%) pregnancies in 13 women were complicated by platelet antibodies; 10 of these patients had alloantibodies prior to the start of pregnancy and in three cases the antibody titres developed during pregnancy. The antibodies were against either GPIIb/IIIa (6/22) or HLA (3/22) or both (4/22). The mode of delivery was recorded in 35 pregnancies, with normal vaginal delivery in 19/35 (54%), elective caesarean section in 11/35 (31%) and emergency caesarean section was performed in 5/35 (14%) either for fetal distress or failed induction of labour. In 29/37 (78%) of the reviewed pregnancies, some form of haemostatic agent was given as prophylaxis at delivery while the remaining eight had no haemostatic support. In almost 90% of pregnancies, platelet transfusions alone were used as prophylaxis at delivery with rVIIa alone in one case and a combination of both in the other two. Importantly, despite prophylaxis, postpartum haemorrhage (PPH) occurred in 40% of the cases, including in the two pregnancies where combination therapy was administered. PPH complicated five of the eight pregnancies (62%) where prophylaxis wasn't given. PPH was primary (within 24 h of delivery) in 13/38 (34%) pregnancies and secondary (more than 24 h to 2 weeks after delivery) in 9/38 (24%) pregnancies, with secondary PPH developing at a median time of 10 days after delivery (range 5-20 days).
With reference to the neonates, 34/41 neonates had no clinical evidence of bleeding. There were three deaths in utero; two from intracranial haemorrhage at 24 and 31 weeks' gestation respectively and there was one miscarriage at 9 weeks' gestation. One neonatal death occurred 48 h after an emergency caesarean section at 28 weeks for reduced fetal movements following an amniocentesis procedure. In all of the pregnancies complicated by fetal or neonatal death, the mothers had platelet alloantibodies. There were three reported cases of thrombocytopenia in otherwise well neonates, two of whose mothers had platelet alloimmunisation. The affected neonates were treated with platelet transfusions.
A more recent review of 65 pregnancies in 34 women with 5 different forms of inherited platelet functional disorders included a sub-group of 20 pregnancies in 10 women with GT (Civaschi et al, 2015) . Although the pre-delivery course of pregnancy was no different to that of the normal population, the high rate of bleeding at delivery described by Siddiq et al (2011) was confirmed. Half of the pregnancies that went on to the 3 rd trimester were complicated by excess bleeding and all the mothers required red cell transfusions with or without platelet transfusions. The study also confirmed the earlier finding that prophylactic platelet transfusions prior to delivery had only limited beneficial effect. In summary, pregnancies in patients with GT are often associated with significant bleeding, particularly during or after delivery. Pregnancies complicated by antiplatelet antibodies are at increased risk of fetal death and neonatal thrombocytopenia.
Management of pregnancy in BSS
One of the difficult issues in patients with BSS is the management of pregnancy, especially pregnancies in mothers with platelet refractoriness and/or anti-platelet antibodies. Maternal alloantibody production can be through sensitisation by prior platelet transfusions but may also occur during pregnancy where maternal antibody production is stimulated by the passage of fetal platelets with a normal paternal GP1b/IX antigen into the maternal circulation. Attempts have been made to reduce the risk of neonatal alloimmune thrombocytopenia in these cases by various methods, including the administration of intravenous immunoglobulins, corticosteroids and plasma exchange.
Until 2014 most of the literature consisted of anecdotal case reports. In a systematic review of these cases (Peitsidis et al, 2010) , 30 pregnancies (including one twin pregnancy) in 18 women with BSS were reported. Four of the women bled during pregnancy; one in the first trimester (5 weeks of gestation) and the other three in the third trimester (36, 38 and 40 weeks of gestation). Antiplatelet antibodies complicated 10 pregnancies in six women; seven with antibodies against GPIb/IX antibody and three with HLA antibodies. Fifty-three per cent (16/30) of the pregnancies were delivered by caesarean section. Primary PPH occurred in 10 cases while secondary PPH developed in 12: 50% of the women with PPH needed red cell transfusions. This is much higher than for the normal maternal population whose likelihood of requiring a per-partum blood transfusion is only between 0Á1% and 1Á2% (Knight et al, 2009) . Platelet transfusions were used in 14 of these cases while four received DDAVP. Bleeding was severe enough in two women to require emergency hysterectomy, one of whom had antiplatelet antibodies (Michalas et al, 1984; Fujimori et al, 1991) .
With regard to fetal outcome, alloimmune thrombocytopenia was reported in 6 neonates with two deaths; one intrauterine death due to severe gastrointestinal bleeding and one neonatal death from intracranial haemorrhage (Fujimori et al, 1991; Peng et al, 1991) . In the other four, the thrombocytopenia presented with cutaneous bleeding in three and the fourth was asymptomatic.
The results from the older literature cited above were not confirmed by a more recent retrospective study of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia (Noris et al, 2014) . This analysis included 30 deliveries in 18 women with bBBS and 34 deliveries in 20 women with mBBS.
In the bBBS group described by Noris et al (2014) , only 28%, as opposed to 53% in the earlier literature review (Peitsidis et al, 2010) , had pre-delivery platelet transfusions and a smaller number of women had caesarean sections: 38% vs. 53%. The greatest differences were in the rate of excessive bleeding and the need for blood transfusions. In the 2010 review, 18/30 (60%) of pregnancies in women with BSS were complicated by either primary or secondary postpartum haemorrhage (PPH) and 15/30 (50%) required blood transfusions. In contrast, in the 2014 study only 3/ 21 (14Á3%) women had excessive blood loss and only 1/21 (4Á8%) received a blood transfusion. Noris et al (2014) considered that their bBBS group may have had a better pre-pregnancy bleeding phenotype than those in the literature review by Peitsidis et al (2010) and they may also have preselected a less severe phenotype as those with more severe bleeding history may have decided not to become pregnant. They also noted that the 2010 study may have been susceptible to reporting bias of those pregnancies with poorer outcomes. Thus the 2010 review paper may have over-estimated the bleeding risk at delivery in bBSS pregnancies.
There were 39 completed pregnancies in the mBSS cohort of study reported by Noris et al (2014) ; 10 (26%) had caesarean sections; none had prophylactic platelet transfusions to cover delivery. The rate of excess bleeding and transfusion was similar to the bBSS group with 5/39 (12Á8%) having excess bleeding and only 1/39 (2Á6%) requiring a blood transfusion.
In summary, the risk of maternal bleeding and poor fetal/ neonatal outcome in BSS is uncertain but the risk of PPH and the need for red cell transfusion may be lower than reported in the pre-2014 literature. There is a significant risk of alloimmune thrombocytopenia in the neonates.
Guidance for the management of pregnancy in GT and BSS
The current UKHCDO guidelines for pregnancy in women with severe platelet disorders, including GT and BSS, recommends prophylaxis against bleeding in all cases at delivery (Bolton-Maggs et al, 2006) . The standard practice based on these guidelines for vaginal delivery would be to give rVIIa at 90 lg/kg immediately pre-delivery in combination with an anti-fibrinolytic agent. rVIIa should be repeated at twohourly intervals for a minimum of three to four doses. Platelet transfusions with HLA-matched platelets should be considered an alternative to rVIIa for vaginal delivery and as first-line prophylaxis in the setting of caesarean section. This advice may need to be reviewed considering the findings of more recent papers outlined above (Noris et al, 2014; Civaschi et al, 2015) .
Maternal alloimmunisation may be associated with fetal or neonatal thrombocytopenia and, as such, it is currently recommended that all women with GT are monitored for alloimmunisation from the time pregnancy is confirmed and throughout its course. Rising maternal alloantibody titres or a previous pregnancy complicated by fetal thrombocytopenia should be considered as significant risk factors for fetal outcome. The neonatal platelet count should be tested at birth. (Please see Table I for a suggested management plan for pregnant females with BSS or GT.) Table I . Principles of management of pregnancy in BSS and GT.
Pre-pregnancy counselling • Review the diagnosis of BSS or GT • Discuss the genetic inheritance with the couple • In consanguineous parents, the father should be screened to identify at-risk fetuses • If both parents are carriers, offer prenatal diagnosis options • Warn about the significant risk of haemorrhage at the time of delivery, which may be life threatening and may, in some cases, require hysterectomy Antenatal • Manage in a specialised unit where senior expertise, appropriate blood products and laboratory monitoring are immediately available • Check for HLA and platelet glycoprotein antibodies in preparation for the need for platelets • Written birth plan for obstetric and haematological management should be prepared in a timely fashion, known to all the relevant staff and available in the hand-held notes Labour • Regional anaesthesia is contraindicated because haemostasis cannot be guaranteed. As such, discussion for pain relief and anaesthetist involvement in case of the need for caesarean section should be discussed in advance.
• Given that uterine atony and consequent bleeding can be troublesome, active management of the second stage should be considered (e.g. uterotonics).
• To prevent excess bleeding during vaginal delivery, rVIIa may be used in combination with tranexamic acid. If bleeding continues despite this treatment, HLA-selected platelets should be infused.
• For caesarean section, HLA-matched platelets and tranexamic acid are recommended as first-line treatment though cannot be relied upon to prevent PPH and may need to be combined with rVIIa Neonate • The neonate is not at risk of inheriting BSS or GT unless the father is a carrier, but it needs to be borne in mind that individuals who are heterozygous for BSS may have milder symptoms.
• If the neonate is at risk, instrumental delivery and fetal scalp monitoring are contraindicated • Neonates of mothers with antiplatelet antibodies are at risk of alloimmune thrombocytopenia, which can cause intracranial haemorrhage • All neonates of a GT or BSS mother should have a full blood count Postpartum • Thromboprophylaxis should be considered on an individual basis, especially if recombinant factor VIIa has been given.
• Postpartum haemorrhage may occur many days after delivery (up to 8 weeks). Therefore, patients should be closely monitored and given contact details for reporting excess bleeding BSS, bernard soulier syndrome; GT, glanzmann thrombasthenia; HLA, human leucocyte antigen; PPH, post-partum haemorrhage; rVIIa, recombinant activated factor VII. 
Conclusion
There is no single consistent approach to the management of GT and BSS, even for an individual patient. Different clinical situations, including pregnancy, will need to be planned appropriately, considering the severity of the bleeding, the nature of the invasive procedure to be undertaken and the presence or not of platelet refractoriness. The only common principle is that all GT and BSS patients should be managed by centres specialising in the management of bleeding disorders with 24-h access to informed, specialist advice.
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